Evidence map›Paper›PMID 41838747›Full record

Trial reportPloS one2026

Helping primary care providers recognize and respond to medication non-adherence and drug-drug interactions: A randomized-controlled clinical utility trial in a value-based care setting.

Trever Burgon, David Paculdo, Joshua Schrecker, Kelsy Gibson Ferrara, Randy E David, Steven Johnson, Czarlota Valdenor, John W Peabody

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05658653 (Measuring the Clinical Utility of Aegis's Chronic Disease Management Test Among VillageMD Providers), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05658653 nacompletednot on this map

Measuring the Clinical Utility of Aegis's Chronic Disease Management Test Among VillageMD Providers: A CPV Randomized Control Trial

TypeinterventionalSponsorQure Healthcare, LLCRan2022 to 2023Enrolled166ConditionsChronic Disease, Drug Drug Interaction, Medication AdherenceArmsEducational Materials for Chronic Disease Management Test (CDMT)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Trever BurgonQURE Healthcare, Saint Louis, Missouri, United States of America.
David PaculdoQURE Healthcare, Saint Louis, Missouri, United States of America.ORCID https://orcid.org/0000-0002-2184-4603
Joshua SchreckerAegis Sciences Corporation, Nashville, Tennessee, United States of America.
Kelsy Gibson FerraraQURE Healthcare, Saint Louis, Missouri, United States of America.
Randy E DavidQURE Healthcare, Saint Louis, Missouri, United States of America.ORCID https://orcid.org/0000-0003-0659-2492
Steven JohnsonQURE Healthcare, Saint Louis, Missouri, United States of America.ORCID https://orcid.org/0009-0008-5592-5269
Czarlota ValdenorQURE Healthcare, Saint Louis, Missouri, United States of America.
John W PeabodyQURE Healthcare, Saint Louis, Missouri, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the clinical utility of a novel chronic disease management test among primary care providers practicing in a value-based care setting. The study assessed the ability of primary care providers to recognize and respond to medication nonadherence (MNA), drug-drug interactions (DDIs), and disease progression.

designA pre-post experimental randomized controlled trial of primary care providers in the same practice setting caring for simulated patients with chronic disease. SETTING AND

participants139 licensed primary care providers (MD, DO, NP, or PA) at a large, multi-state primary care practice in the United States.

interventionBoth intervention and control group participants cared for three simulated chronic disease patients at baseline and again after the intervention. After baseline, intervention group participants reviewed educational materials about a new saliva-based chronic disease management test that detects MNA and DDI and were then provided with the test's results in simulation; the control group did not have access to the test results. PRIMARY OUTCOME MEASURES: Changes in care decisions between the two groups were analyzed using a difference-in-differences approach to determine whether routine testing in the outpatient setting changed correct identification and management of medication nonadherence (MNA), drug-drug interactions (DDI), and disease progression.

resultsThe intervention group participants were significantly more likely to make the correct diagnosis of MNA (control: 10.0% vs intervention: 80.0%, p < 0.001) and DDI (control: 18.6% vs intervention: 52.9%, p < 0.001) and to recommend an appropriate treatment for MNA (control: 25.7% vs intervention: 54.3%, p = 0.001) and DDI patients (control: 27.1% vs intervention: 58.8%, p < 0.001).

conclusionPrimary care providers with results from a definitive saliva-based test for MNA and DDI were significantly more likely to identify those common challenges and make appropriate updates to the patient's treatment plan. This has important implications for improving quality and value, especially for the millions of patients with chronic conditions on multiple medications.

trial registrationClinicalTrials.gov, NCT05658653, Registered 2-Dec-2022.

Indexed as

Medication AdherenceAdherence InterventionsAdultChronic DiseaseDrug InteractionsFemaleHumansMaleMiddle AgedPrimary Health Care

Identifiers

PMID41838747
PMCPMC12991271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.